Tag Archives: TG Therapeutics

H.C. Wainwright Keeps Their Buy Rating on TG Therapeutics (TGTX)

H.C. Wainwright analyst Edward White reiterated a Buy rating on TG Therapeutics (TGTX – Research Report) today and set a price target of $20.00. The company’s shares closed last Monday at $7.68. According to TipRanks.com, White is a 5-star analyst

H.C. Wainwright Keeps a Buy Rating on TG Therapeutics (TGTX)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $20.00. The company’s shares closed last Monday at $6.44. According to TipRanks.com, White is

The CEO & President of TG Therapeutics (NASDAQ: TGTX) is Buying Shares

Today, the CEO & President of TG Therapeutics (TGTX – Research Report), Michael S. Weiss, bought shares of TGTX for $351.5K. See today’s analyst top recommended stocks >> The Company has a Price to Book ratio of 32.0979. Currently, TG

Analysts’ Top Healthcare Picks: TG Therapeutics (TGTX), Checkpoint Therapeutics Inc (CKPT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TG Therapeutics (TGTX – Research Report), Checkpoint Therapeutics Inc (CKPT – Research Report) and uniQure NV (QURE – Research Report) with bullish

TG Therapeutics (TGTX) Receives a Buy from Cantor Fitzgerald

In a report released yesterday, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $17. The company’s shares closed on Friday at $7.56. Young commented: “: We reiterate

H.C. Wainwright Maintains a Buy Rating on TG Therapeutics (TGTX)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $20. The company’s shares opened today at $8.17. White said: “Our $20 price target